Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aprea AB; Aprea Therapeutics

Criteria

Summary criteria for participant selection:

Inclusion Criteria:

• Male or female ≥ 18 years of age.

• Any below mentioned advanced disease, which is not eligible for other therapies. The diagnosis should have been confirmed either histologically or cytologically:

1. Acute myeloid leukemia.

2. Acute lymphoid leukemia.

3. Chronic lymphocytic leukemia.

4. Chronic myeloid leukemia.

5. Chronic myelomonocytic leukemia.

6. Multiple myeloma.

7. Non Hodgkin's lymphoma.

8. Hodgkin's lymphoma.

9. Myelodysplastic syndrome.

10. Myelofibrosis.

11. Hormone refractory, metastatic prostate carcinoma.